Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea
· Delayed Price · Currency is KRW 149,600
-2,300 (-1.51%)
At close: Apr 29, 2026
Daewoong Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 1,747,802 | 1,982,530 | 1,454,393 | 1,343,932 | 1,754,469 | 1,638,243 | Upgrade
|
| Market Cap Growth | 27.75% | 36.31% | 8.22% | -23.40% | 7.09% | -7.75% | Upgrade
|
| Enterprise Value | 2,532,953 | 2,726,264 | 2,099,040 | 1,735,899 | 2,148,696 | 2,022,062 | Upgrade
|
| Last Close Price | 151900.00 | 172300.00 | 125964.64 | 115832.21 | 156366.58 | 145448.14 | Upgrade
|
| PE Ratio | 8.92 | 10.12 | 58.80 | 11.04 | 41.54 | 66.85 | Upgrade
|
| Forward PE | 10.54 | 11.76 | 14.39 | 14.77 | 22.77 | 41.35 | Upgrade
|
| PS Ratio | 1.11 | 1.26 | 1.02 | 0.98 | 1.37 | 1.42 | Upgrade
|
| PB Ratio | 1.54 | 1.75 | 1.51 | 1.43 | 2.37 | 2.35 | Upgrade
|
| P/TBV Ratio | 2.02 | 2.29 | 2.24 | 2.15 | 3.79 | 3.83 | Upgrade
|
| P/FCF Ratio | - | - | - | 50.39 | 33.11 | 150.21 | Upgrade
|
| P/OCF Ratio | 11.71 | 13.29 | 28.25 | 9.88 | 14.84 | 40.96 | Upgrade
|
| PEG Ratio | 1.67 | 0.19 | 1.07 | 0.78 | 0.39 | 0.24 | Upgrade
|
| EV/Sales Ratio | 1.61 | 1.74 | 1.48 | 1.26 | 1.68 | 1.75 | Upgrade
|
| EV/EBITDA Ratio | 8.65 | 11.06 | 10.81 | 10.53 | 15.86 | 15.60 | Upgrade
|
| EV/EBIT Ratio | 10.48 | 13.95 | 14.45 | 14.33 | 22.43 | 22.79 | Upgrade
|
| EV/FCF Ratio | -59.84 | - | - | 65.09 | 40.55 | 185.40 | Upgrade
|
| Debt / Equity Ratio | 0.73 | 0.73 | 0.68 | 0.47 | 0.60 | 0.64 | Upgrade
|
| Debt / EBITDA Ratio | 3.36 | 3.36 | 3.34 | 2.68 | 3.30 | 3.44 | Upgrade
|
| Debt / FCF Ratio | - | - | - | 16.55 | 8.43 | 40.87 | Upgrade
|
| Net Debt / Equity Ratio | 0.58 | 0.58 | 0.55 | 0.32 | 0.41 | 0.39 | Upgrade
|
| Net Debt / EBITDA Ratio | 2.66 | 2.66 | 2.74 | 1.84 | 2.26 | 2.10 | Upgrade
|
| Net Debt / FCF Ratio | -15.51 | -15.51 | -5.14 | 11.38 | 5.78 | 24.94 | Upgrade
|
| Asset Turnover | 0.72 | 0.72 | 0.76 | 0.83 | 0.86 | 0.83 | Upgrade
|
| Inventory Turnover | 2.64 | 2.64 | 2.77 | 3.06 | 3.39 | 3.54 | Upgrade
|
| Quick Ratio | 0.66 | 0.66 | 0.55 | 0.47 | 0.68 | 0.72 | Upgrade
|
| Current Ratio | 1.24 | 1.24 | 1.03 | 0.86 | 1.16 | 1.13 | Upgrade
|
| Return on Equity (ROE) | 18.40% | 18.40% | 2.45% | 14.27% | 5.44% | 4.32% | Upgrade
|
| Return on Assets (ROA) | 5.63% | 5.63% | 4.84% | 4.54% | 4.03% | 3.99% | Upgrade
|
| Return on Invested Capital (ROIC) | 11.45% | 11.90% | 4.38% | 10.40% | 9.50% | 9.18% | Upgrade
|
| Return on Capital Employed (ROCE) | 11.00% | 11.00% | 10.50% | 11.00% | 8.80% | 9.30% | Upgrade
|
| Earnings Yield | 11.21% | 9.88% | 1.70% | 9.06% | 2.41% | 1.50% | Upgrade
|
| FCF Yield | -2.42% | -2.14% | -7.13% | 1.98% | 3.02% | 0.67% | Upgrade
|
| Dividend Yield | 0.40% | 0.35% | - | - | - | - | Upgrade
|
| Payout Ratio | 4.12% | 4.12% | 31.30% | 5.98% | 19.10% | 26.35% | Upgrade
|
| Buyback Yield / Dilution | - | - | -0.71% | -3.21% | -0.59% | -3.21% | Upgrade
|
| Total Shareholder Return | 0.40% | 0.35% | -0.71% | -3.21% | -0.59% | -3.21% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.